Bioventus Inc.
A maker of orthobiologic therapies that help the body heal itself, Bioventus Inc. sells the EXOGEN ultrasound bone-healing system and Durolane joint injections for osteoarthritis, giving patients non-surgical options for orthopedic care. Founded in 2012 in Durham, North Carolina, the company was spun out of medical-technology firm Smith & Nephew. Its name blends the Greek word for life with the Latin for wind — fittingly, EXOGEN itself began as a separate company before joining the lineup.
Bought 176.9K
Granted 117.5K
Granted 111.9K · Bought 2.35M
Granted 2.78M
Granted 209.6K · Bought 88.0K
Bought 164.9K
Granted 271.5K · Sold 65.1K
Granted 237.5K · Bought 1.0K · Sold 59.9K
Granted 117.5K · Sold 10.0K
Granted 254.7K · Bought 1.0K · Sold 33.4K
Granted 138.2K
Granted 221.0K · Sold 28.8K
Granted 117.5K
Granted 111.3K
Granted 108.7K
Granted 174.1K · Bought 500 · Sold 66.6K
Granted 107.0K · Sold 29.7K
Granted 83.0K · Bought 2.5K · Sold 22.2K
Granted 70.0K · Bought 6.0K · Sold 1.3K
Granted 44.0K
Bought 11.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bartholdson John A. +2 co-filersDirector, 10% owner, 10% owner · 3 transactions | — | 13.66Mas of Aug 2023 | — | 176.9K | — |
| Sutter Martin PDirector, 10% owner · 6 transactions | — | 13.14M | 117.5K | — | — |
| Bartholdson John A.Director, 10% owner · 17 transactions | — | 7.05M | 111.9K | 2.35M | — |
| Vizirgianakis Stavros G.Director · 2 transactions | — | 2.78Mas of Jun 2022 | 2.78M | — | — |
| Hawkins William ADirector · 10 transactions | — | 297.6K | 209.6K | 88.0K | — |
| Bihl Anthony P IIIInterim CEO, Director · 3 transactions | — | 289.9Kas of Aug 2023 | — | 164.9K | — |
| Singleton Mark LeonardSVP & CFO · 26 transactions | — | 183.0K | 271.5K | — | 65.1K |
| D'Adamio AnthonySVP & General Counsel · 33 transactions | — | 158.0K | 237.5K | 1.0K | 59.9K |
| Nohra Guy PDirector · 8 transactions | — | 148.9K | 117.5K | — | 10.0K |
| Pavesio AlessandraSVP & Chief Science Officer · 7 transactions | — | 148.3Kas of Apr 2022 | 254.7K | 1.0K | 33.4K |
| Stalnecker Susan MDirector · 6 transactions | — | 138.2K | 138.2K | — | — |
| Claypoole Robert EPresident and CEO, Director · 6 transactions | — | 135.9K | 221.0K | — | 28.8K |
| Neels Guido JDirector · 6 transactions | — | 117.5K | 117.5K | — | — |
| Ladone Mary KayDirector · 7 transactions | — | 111.3K | 111.3K | — | — |
| Beyer PatDirector · 7 transactions | — | 108.7K | 108.7K | — | — |
| Nosenzo JohnFmr. Chief Commercial Officer · 10 transactions | — | 87.1Kas of Oct 2022 | 174.1K | 500 | 66.6K |
| McMurry-Heath MichelleDirector · 9 transactions | — | 77.3K | 107.0K | — | 29.7K |
| Church Katrina JSVP & Chief Compliance Officer · 32 transactions | — | 64.2K | 83.0K | 2.5K | 22.2K |
| Anglum Gregory O.SVP & CFO · 5 transactions | — | 55.0Kas of Feb 2022 | 70.0K | 6.0K | 1.3K |
| Cowdy Philip G.Director · 3 transactions | — | 44.0K | 44.0K | — | — |
| Reali Kenneth MichaelCHIEF EXECUTIVE OFFICER, Director · 2 transactions | — | 20.6Kas of Sep 2021 | — | 11.2K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +2.48M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.